The California Institute for Regenerative Medicine grants Sangamo BioSciences (SGMO) a $6.4M...


The California Institute for Regenerative Medicine grants Sangamo BioSciences (SGMO) a $6.4M award to develop its ZFP-genome editing technology for the treatment of beta-thalassemia with the ultimate goal of eliminating the need for chronic blood transfusions in patients. SGMO says "the four year grant provides matching funds for preclinical work that will support an IND application and a Phase 1 clinical trial." A recent article by SA contributor Life Sciences Report favorably mentions companies (like SGMO) with platform technologies. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs